Research and Development
Cancer - Scientists are employing innovative molecular biology tools that will allow identification and validation of the critical targets for cancer drug discovery and diagnostic development. Using an integrated approach, we aim to combine specific anti-cancer drugs with diagnostic tests, thereby improving the treatment of cancer by selecting suitable patients and monitoring the progress of therapy. The overall goal is to make cancer therapy more personalized, safer and more effective, thus reducing overall cancer morbidity and mortality. With a broad portfolio of tumor markers for prostate, colorectal, liver, ovarian, breast, stomach, pancreatic and lung cancer, as well as a range of molecular oncology tests, Roche will continue to be a leader in providing cancer-focuses treatments and diagnostics.
Inflammation - Inflammatory diseases affect millions of people around the globe, leading to pain, disability, disfigurement and in some cases, death. In this area, we seek ways to uncover new approaches to treating a range of diseases including severe asthma, chronic obstructive pulmonary disease (COPD) and rheumatoid arthritis. Our vision is to become the leader in inflammation by shaping future treatment and rebuilding patients' lives.
Metabolism - In this area, research is focused around a portfolio that combines first- and/or best-in-class compounds. Metabolic diseases involve research into new ways of treating diabetes, dyslipidemia and cardiovascular disease. As type 2 diabetes and dyslipidemia are rapidly expanding disease states with significant unmet media need, scientists are focused on developing more effective and clinically differentiated medicines to address them.
RNA Therapeutics - Nutley scientists are exploring the emerging area of RNA interference (RNAi), a revolution in biology, which represents a breakthrough in understanding how genes are turned on and off in cells. RNAi therapeutics targets the cause of diseases by potently silencing specific messenger RNAs (mRNAs), thereby preventing disease-causing proteins from being made. RNAi therapeutics has the potential to treat disease and help patients in a fundamentally new way.
Discovery Technologies - Scientists in this group have expertise in a number of areas including protein cloning and expression, cell line development, microbial fermentation and cell culture production, protein purification, biochemical and cell-based assay development, high throughput screening, monoclonal antibody development, automation technology, compound profiling and high content screening. Their efforts support research in oncology, metabolism and inflammation.